Current advances in anti-influenza therapy

Area of Science:

• Virology
• Pharmacology
• Infectious Diseases

Background:

• Influenza epidemics cause significant mortality and morbidity globally.
• Emergence of novel influenza strains, like swine-origin A/H1N1, poses pandemic threats.
• Traditional antivirals (amantadine, ribavirin, zanamivir, oseltamivir) face limitations due to toxicity and drug resistance.

Purpose of the Study:

• To review advances in anti-influenza therapy over the last decade.
• To compare traditional virus-based strategies with novel cell-based approaches.
• To classify anti-influenza compounds by chemical structure, synthesis, and structure-activity relationships.

Main Methods:

• Literature review of anti-influenza therapies published in the last 10 years.
• Classification of antiviral compounds based on chemical structure and mechanism of action.
• Analysis of synthetic pathways and structure-activity relationships for key compounds.

Main Results:

• Traditional antivirals targeting viral replication show limited efficacy due to resistance.
• Novel cell-based strategies targeting host cell pathways offer potential for broad-spectrum activity.
• Intracellular redox state modulation presents a promising avenue for inhibiting influenza replication.

Conclusions:

• Developing antivirals targeting host cell pathways is crucial for combating influenza.
• Cell-based strategies may overcome limitations of traditional virus-specific drugs.
• Further research into structure-activity relationships can guide the development of next-generation anti-influenza therapeutics.